**Translation of Immediate Report Filed by Elron Ventures on November 13, 2025 with the Israeli Securities Authority**

Re: Update regarding the investment in Notal Vision

Elron Ventures Ltd. (TASE: ELRN) ("Elron" or the "Company") hereby announces that pricing was determined in the U.S. by the Centers for Medicare and Medicaid Services (CMS) for the reimbursement code that applies to the diagnostic service that is provided by the Notal Vision Monitoring Center utilizing the SCANLY Home OCT ("SCANLY") medical device that is marketed by Notal Vision Inc. ("Notal Vision"), a company held by Elron.

SCANLY enables remote monitoring of the retinal health of wet age-related macular degeneration (AMD) patients between clinic visits, using AI analysis of Optical Coherence Tomography (OCT) scans that patients take themselves. AMD is most common in people over the age of 55.

CMS is a U.S. federal agency that administers the major U.S. health insurance programs, including Medicare for people aged 65 and over. The aforementioned code (CPT code 0605T) refers to the technical component of remote retinal OCT imaging, and will take effect in 2026.

As conveyed to the Company by Notal, CMS's decision to establish pricing for home OCT indicates its importance for Medicare beneficiaries, with the pricing rate benefiting Notal.

Reimbursement for use of SCANLY is subject to a decision by the local Medicare Administrative Contractor to cover the cost of the diagnostic monitoring service in 2026. There is no assurance that such a decision will be taken, or that the decision will apply to the entire target population of SCANLY.

The Company holds approximately 8% of the issued share capital of Notal and 6% on a fully diluted basis and as of June 30, 2025, the investment in Notal was treated as a financial asset measured at fair value through profit or loss, which was estimated at approximately $7.15 million. At this stage, the Company is not yet able to estimate the impact of the aforementioned event on the measurement of the fair value of the investment in Notal. This value will be measured in the annual financial statements for 2025 with the assistance of an external valuer.

For a description of Notal see section 2.3. of Part I of Elron's Annual Report for 2024.

**Date and time the corporation first became aware of the event or matter:** November 12, 2025, at 15:30.

The Company notes that the information was published on the CMS website on November 5, 2025; however, the Company did not receive notification until November 12, 2025.